

Poster Titles and Authors

Session 1 - Wednesday

Imaging

- (a1) **Magnetic resonance imaging of the spinal cord provides a marker of the rate of progression in ALS patients**
Khamyasa M, Lefort M, Pélégriani-Issac M, Devos D, Rolland A-S, Marchand-Pauvert V, Pradat P-F
- (a2) **Combined microstructural and sodium homeostasis alterations in ALS are widespread in fast progressors: a brain DTI and sodium MRI study**
Mohamed Mounir EL MENDILI, Aude-Marie GRAPPERON, MD, Rémi DINTRICH, Jan Patrick STELLMANN, Jean-Philippe RANJEVA, Maxime GUYE, Annie VERSCHUEREN, Shahram ATTARIAN, Wafaa ZAARAOUI
- a3) **Cross Frequency Coupling Analysis in Amyotrophic Lateral Sclerosis resting-state EEG**
Cristina Benetton*, Alexandra Lackmy-Vallee, Michel Le Van Quyen, Caroline Rouaux, Pierre-Francois Pradat, Véronique Marchand-Pauvert
- (a4) **Altered resting-state EEG microstates in ALS, associated with distinct sources of brain activity**
Marjorie Metzger*, Stefan Dukic, Roisin McMackin, Eileen Giglia, Matthew Mitchell, Saroj Bista, Emmet Costello, Colm Peel, Yasmine Tadjine, Vladyslav Sirenko, Serena Plaitano, Amina Coffey, Lara McManus, Teresa Buxo, Antonio Fasano, Mark Heverin, Peter Bede, Muthuraman Muthuraman, Niall Pender, Orla Hardiman, † Bahman Nasseroleslami †
- (a5) **Profiling brain morphologic features of motor neuron disease caused by TARDBP mutations: an MRI-based study**
Alma Ghirelli*, Federica Agosta, Edoardo Gioele Spinelli, Nilo Riva, Elisa Canu, Veronica Castelnovo, Teuta Domi, Laura Pozzi, Paola Carrera, Adriano Chiò, Vincenzo Silani, Massimo Filippi
- (a6) **Structural and functional connectome alterations across King's stages in amyotrophic lateral sclerosis**
Edoardo Gioele Spinelli, Alma Ghirelli, Silvia Basaia, Camilla Cividini, Nilo Riva, Tommaso Russo, Elisa Canu, Veronica Castelnovo, Massimo Filippi, Federica Agosta
- (a7) **Functional connectivity reorganization propagating from disease epicenters in frontotemporal dementia variants**
Edoardo Gioele Spinelli, Silvia Basaia, Camilla Cividini, Francesco Falbo, Costanza Pavone, Nilo Riva, Elisa Canu, Veronica Castelnovo, Giuseppe Magnani, Francesca Caso, Paola Caroppo, Sara Prioni, Cristina Villa, Lucio Tremolizzo, Ildebrando Appollonio, Vincenzo Silani, Keith A Josephs, Jennifer L Whitwell, Massimo Filippi, Federica Agosta
- (a8) **Disruption of the structural connectivity and of hypothalamic integrity in ALS patients and murine models**
Francesco Roselli, David Bayer, Hans-Peter Müller, Rami Saad, Stefano Antonucci, Luc Dupuis, Albert Ludolph, Jan Kassubek

- (a9) **Are short intracortical inhibition (SICI) and intracortical facilitation (ICF) abnormal in ALS patients? – A threshold tracking TMS study**
Roisin McMackin, Yasmine Tadjine, Friedemann Awiszus, Antonio Fasano, Mark Heverin, Bahman Nasserroleslami, Richard G. Carson, Orla Hardiman
- (a10) **The effects of background audio-visual processing on the TMS measures of cortical excitability for biomarker research in ALS**
Yasmine S. Tadjine*, Friedemann Awiszus, Mark Heverin, Bahman Nasserroleslami, Orla Hardiman, Roisin McMackin
- (a11) **Brain-age predicts survival in ALS**
Andreas Hermann*, Gaël Nils Tarakdjian, Anna Gesine Marie Temp, Elisabeth Kasper, Judith Machts, Jörn Kaufmann, Stefan Vielhaber, Johannes Prudlo, James H. Cole, Stefan Teipel, Martin Dyrba
- (a12) **Preliminary magnetoencephalography findings in active and passive motor task in ALS**
*Tobias Sevelsted Stærmosé, Lau Møller Andersen, Sarang S. Dalal, Christopher J. Bailey, Jakob Udby Blicher
- (a13) **Impaired Cortico-muscular Synchrony in ALS during Transient and Sustained Voluntary Movements**
Saroj Bista*, Amina Coffey, Antonio Fasano, Stefan Dukic, Teresa Buxo, Matthew Mitchell, Lara McManus, Roisin McMackin, Eileen Giglia, Mark Heverin, Muthuraman Muthuraman, Orla Hardiman, Bahman Nasserroleslami
- (a14) **The Spinal Cord Lateral Tract Sign in Amyotrophic Lateral Sclerosis: an rAMIRA based MRI sign for Upper Motor Neuron Involvement in a Clinical Setting**
Maria Janina Wendebourg*, Laura Sander, Eva Maria Kesenheimer, Matthias Weigel, Tanja Haas, Claudia Weidensteiner, Christoph Neuwirth, Nathalie Braun, Markus Weber, Kathleen Jahn, Cristina Granziera, Kathi Schweikert, Michael Sinnreich, Oliver Bieri, Regina Schlaeger
- (a15) **Cervical Spinal Cord Gray Matter Atrophy as an emerging biomarker in Amyotrophic Lateral Sclerosis**
Eva Maria Kesenheimer*, Maria Janina Wendebourg, Matthias Weigel, Nicole Naumann, Kathleen Jahn, Tanja Haas, Laura Sander, Nathalie Braun, Christoph Neuwirth, Cristina Granziera, Markus Weber, Kathi Schweikert, Michael Sinnreich, Oliver Bieri, and Regina Schlaeger
- (a16) **Brain metabolic differences between pure bulbar and pure spinal ALS**
Antonio Canosa*, Alessio Martino, Alessandro Giuliani, Cristina Moglia, Rosario Vasta, Maurizio Grassano, Francesca Palumbo, Sara Cabras, Francesca Di Pede, Filippo De Mattei, Vincenzo Arena, Umberto Manera, Andrea Calvo, Marco Pagani, Adriano Chiò
- (a17) **Radiological biomarkers of ALS using a clinically-validated web-based analysis MRI platform**
Hugo Kermorvant, Muriel Lefort, Mohammed Khamaysa, Arnaud Preuilh, Véronique Marchand-Pauvert, Mélanie Pellegrini-Issac, Didier Cassereau, Vincent Perlberg, Pierre-François Pradat
- (a18) **Resting state fmri functional connectome of C9orf72 mutation status**
Anna Nigri, Mario Stanziano, Umberto Manera, Davide Fedeli, Stefania Ferraro, Sara Palermo, Federica Agosta, Laura Lequio, Consuelo Valentini, Antonio Canosa, Andrea Calvo, Adriano Chiò, Maria Grazia Bruzzone, Cristina Moglia

Biomarkers

- (b19) **Profiling of non-coding RNA as biomarkers in cerebrospinal fluid of amyotrophic lateral sclerosis patients**
Greig Joilin*, Elizabeth Gray, Alexander G Thompson, Kevin Talbot, P. Nigel Leigh, Sarah F Newbury, Martin R Turner, Majid Hafezparast
- (b20) **Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of Amyotrophic Lateral Sclerosis**
Hugo Alarcán*, Mélanie Berthet, Laura Suire, Corentin Colas, Loïc Gonzalez, Christophe Paget, Isabelle Benz-de Bretagne, Eric Piver, Patrick Vourc'h, Christian Andres, Philippe Corcia, Hélène Blasco
- (b21) **CfDNA-miRNA based multiplexed biomarker system for ALS**
Iddo Magen*, Nancy Yacovzada, Hai Zemmour, Ruth Shemer, Yuval Dor, Eran Hornstein
- (b22) **Thiol/disulphide homeostasis in Amyotrophic Lateral Sclerosis**
Hilmi, Uysal*; Fatih, Özcan; Cansu, Aydın Kaya; Rabia, Bice; Salim, Neşelioğlu; Özcan, Erel
- (b23) **“OMICS” Profiling of plasma-derived exosomes: the search of biomarkers for early-stage ALS**
Lanznaster D, Dangomau A, Bruno C, Vourc'h P, Corcia P, Andres CR, Duguez S, Duddy W, Blasco H
- (b24) **isomiRs - a novel family of molecular biomarkers for ALS prognostication**
Yahel Cohen*, Iddo Magen, Nancy-Sarah Yacovzada, Andrea Malaspina, Michael Benatar & Eran Hornstein
- (b25) **Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics**
Arvin Behzadi*, Fani Pujol-Calderón, Anton E. Tjust, Anna Wuolikainen, Kina Höglund, Karin Forsberg, Erik Portelius, Kaj Blennow, Henrik Zetterberg, Peter Munch Andersen
- (b26) **Deep proteomics of cerebrospinal fluid for biomarker identification in ALS**
Elizabeth R Dellar*, Iolanda Vendrell, Simon Davis, Kevin Talbot, Benedikt Kessler, Roman Fischer, Martin R Turner, Alexander G Thompson
- (b27) **Repeaters as an index of disease progression in ALS**
Dimitra Veltsista*, Konstantina Kaskani, Elisabeth Chroni
- (b28) **The role of plasma CHI3L1 levels in Amyotrophic Lateral Sclerosis**
Alessandro Bombaci*, Giovanni De Marco, Federico Casale, Paolina Salamone, Giuseppe Fuda, Giulia Marchese, Cristina Moglia, Andrea Calvo, Adriano Chiò
- (b29) **Underscoring the role of fatty acid elongation in ALS**
Maddi Garciandia-Arcelus*, Gorka Fernández-Eulate, José Ignacio Ruíz-Sanz, Andrés Jiménez, Laura Rodríguez, Javier Riancho, Raul Domínguez, Gorka Gereú, Roberto Fernández-Torrón, Juan José Poza-Aldea, Jon Ondaro, Juan Bautista-Espinal, Jesus Maria Aizpurua, Gonzalo González-Chinchón, Miren Zulaica, Maria Begoña Ruiz-Larrea, Mónica Povedano, Adolfo López de Muinain, Francisco Javier Gil-Bea

Genomics

- (c30) **“When the odds are down to the toss of a coin...”: pre-symptomatic genetic testing amongst people at an increased risk of inherited MND**
Jade Howard*, Karen Forrest Keenan, Fadhila Mazanderani, Louise Locock
- (c31) **Common genetic polymorphisms of inflammation and oxidative stress genes modify ALS**
Metka Ravnik-Glavač*, Katja Goričar, David Vogrinc, Blaž Koritnik, Jakob Lavrenčič, Damjan Glavač, Vita Dolžan
- (c32) **TBK1 p.E696K mutation causes autophagolysosomal dysfunction and ALS/FTD-like symptoms but not inflammation in mice**
David Brenner*, Kirsten Sieverding*, Susanne Zellner, Christopher Secker, Karsten Nalbach, Rüstem Yilmaz, Shady Amr, Jonathan Uhl, Johanna Hollenbeck, Christian S. Lobsiger, Christian Münch, Karin Danzer, Deniz Yilmazer-Hanke, Axel Freischmidt, Martina Schifferer, Rosanna Parlato, Christian Behrends, and Jochen H. Weishaupt *Equal contribution
- (c33) **Genetic Analysis of ALS in Norway (“GAIN”)**
Cathrine Goberg Olsen*, Øyvind Løvold Busk, Tori Navestad Aanjesen, Karl Bjørnar Alstadhaug, Ingrid Kristine Bjørnå, Geir Julius Braathen, Kristin Lif Breivik, Natasha Demic, Heidi Øyen Flemmen, Erika Hallerstig, Ineke HogenEsch, Øystein Lunde Holla, Anne Berit Jøntvedt, Margitta T. Kampman, Grethe Kleveland, Helene Ballo Kvernmo, Unn Ljøstad, Angelina Maniaol, Åse Hagen Morsund, Ola Nakken, Camilla Novy, Tiina Rekand, Katrin Schlüter, Stephan Schuler, Kristian Tveten, Ole-Bjørn Tysnes, Trygve Holmøy, Helle Høyer
- (c34) **Pathway-level perturbations link the pre-symptomatic synapse in CLN3 disease, spinal muscular atrophy, and ALS**
Rachel A Kline, Maica Llaverro Hurtado, Thomas H Gillingwater, Paul A Skehel, Giuseppa Pennetta, and Thomas M Wishart
- (c35) **ATXN2 as genetic risk factor in Spanish population**
Daniel Borrego-Hernández*, Laura Expósito-Blázquez, Juan Francisco Vázquez-Costa, Raúl Domínguez-Rubio, Alberto Villarejo-Galende, Miguel Ángel Martín-Casanueva, Jesús Esteban-Pérez and Alberto García-Redondo
- (c36) **Assessing the impact of C9orf72 DNA methylation using CRISPR/Cas9-targeted Nanopore sequencing**
Maria Zwartkruis*, Paul Hop, Ramona Zwamborn, Ivo Renkens, Martin Elferink, Carlo Vermeulen, Roy Straver, Joke van Vugt, Leonard van den Berg, W. Ludo van der Pol, Gijs van Haften, Ewout Groen, Jan Veldink
- (c37) **Investigating the role of stress granule composition on C9ORF72-related ALS**
Saygin Bilican*, Franziska Hommen, Angela Johns, David Vilchez
- (c38) **A five-years collection of ALS-related mutations in patients from an Italian Center for Motor Neuron Diseases**
Lucrezia Becattini*, Francesca Bianchi, Lorenzo Fontanelli, Antonella Fogli, Gabriele Siciliano
- (c39) **Unravelling genetic modifiers of ALS caused by mutations in FUS and TDP-43**
Paraskevi Tziortzouda*, Jolien Steyaert, Arun Pal, Katarina Stoklund Dittlau, Adrià Sicart Casellas, Matthieu Moisse, Wendy Scheveneels, Elke Bogaert, Philip Van Damme, Andreas Hermann, Thomas Moens and Ludo Van Den Bosch

- (c40) **ALS/FTD-associated C9orf72 C4G2 repeat RNA disrupts phenylalanine tRNA aminoacylation**
Urša Čerček, Mirjana Malnar, Xiaoke Yin, Manh Tin Ho, Barbka Repic Lampret, Manuela Neumann, Andreas Hermann, Guy Rouleau, Beat Suter, Manuel Mayr, Boris Rogelj*
- (c41) **Characterizing SOD1 mutations in Spain. The impact of genotype, age, and sex in the natural history of the disease**
Juan F Vázquez-Costa*, Daniel Borrego-Hernández, Carmen Paradas, M^a Teresa Gómez-Caravaca, Ricard Rojas-García, Luis Varona, Mónica Povedano, Tania García Sobrino, Ivonne Jericó, Antonio José Gutiérrez-Martínez, Javier Riancho, Janina Turon-Sans, Abdelilah Assialioui, Jordi Pérez-Tur, Teresa Sevilla, Jesús Esteban Pérez, Alberto García-Redondo, on behalf of ALSGESCO
- (c42) **Genome-wide assessment of genetic modifiers in ALS progression**
Ramona Zwamborn*, Michelle de Groot, Project MinE sequencing consortium, Wouter van Rheenen, Jan Veldink
- (c43) **Mutation in ALS associated KIF5A C-terminus promotes protein aggregation**
Shreya Agarwal*, Pietro Zanella, Sala Carlo, Verpelli Chiara, Tobias Böeckers, Alberto Catanese
- (c44) **Targeting C9orf72 repeat-expanded RNAs with antisense FANA oligonucleotides**
Miguel Garavís*, Mansi Parasrampur, Halle Barber, Carlos González, Keith Gagnon, Masad J. Damha
- (c45) **SARM1 variants in a cohort of Italian ALS patients**
Tommaso Russo*, Laura Pozzi, Teuta Domi, Paride Schito, Giovanni Battista Pipitone, Federica Agosta, Paola Carrera, Massimo Filippi, Angelo Quattrini, Nilo Riva
- (c46) **Comparative analysis of the structural dynamics of Superoxide dismutase 1 (SOD1) variants associated with Amyotrophic Lateral Sclerosis**
Munishikha Kalia*, Deborah Ness, Sarah Opie-Martin, Ahmad Al Khleifat, Thomas Spargo, Renata Kabiljo, Ammar Al-Chalabi, Alfredo Iacoangeli
- (c47) **HnRNP A1B, a splice variant of HNRNPA1 dependent on TDP-43, has a novel function in cytoskeleton-dependent transport**
Myriam Gagné*, Marianna Llassera, Christian Trahan, Alicia Dubinski, Asmita Ghosh, Jade-Emmanuelle Deshaies, Sarah Peyrard, Marlene Oeffinger, Christine Vande Velde
- (c48) **Reprogrammed astrocytes from a C9-ALS family with variable penetrance display differential C9orf72 pathology and motor neuron toxicity in co-culture**
Allan C. Shaw*, Iris S. Pasniceanu, Matthew Wyles, Dr Matthew Parker, Dr Adrian Higginbottom, Dr Matthew R. Livesey, Dr Guillaume M. Hautbergue, Professor Laura Ferraiuolo[^], Professor Dame Pamela J. Shaw[^]. [^]These authors contributed equally to this work.
- (c49) **ALSoD: An updated resource linking clinical research and bioinformatics tools in ALS**
Sarah Opie-Martin, Olumbunmi Abel, Peter M Anderson, John Powell, Ammar Al-Chalabi
- (c50) **Use of Next Generation Sequencing to Elucidate the Genetics of Monomelic Amyotrophy (MMA) in Bangladesh and UK patients**
Shaila Haque*, Johnathan Cooper-Knock, Sophie Cadden, Pamela J Shaw, Thomas M Jenkins#, Janine Kirby#

- (c51) **MutaPipe – A Bioinformatics Pipeline to Identify High Quality Mutant and Wildtype PDB Structures for ALS Proteins**
Deborah Ness, Munishikha Kalia, Ammar Al-Chalabi, Alfredo Iacoangeli
- (c52) **GEOexplorer: an R/Bioconductor package for gene expression analysis and visualization**
Guy P Hunt*, Rafael Henkin, Fabrizio Smeraldi, Alfredo Iacoangeli, Michael R Barne
- (c53) **Mitochondrial function determines severity but not risk of amyotrophic lateral sclerosis**
Calum Harvey, Marcel Weinreich, Sai Zhang, Paul J Hop, Ramona A J Zwamborn, Kristel van Eijk, Thomas H Julian, Tobias Moll, Alfredo Iacoangeli, Ahmad Al Khleifat, John P Quinn, Abigail L Pfaff, Sulev Koks, Joanna Poulton, Stephanie L Battle, Dan E Arking, Michael P Snyder, Project MinE ALS Sequencing Consortium, Jan Veldink, Kevin P Kenna, Pamela J Shaw&, Johnathan Cooper-Knock*&
- (c54) **A Knowledge-Based Machine Learning Approach to Gene Prioritisation in Amyotrophic Lateral Sclerosis**
Jiajing Hu, Rosalba Lepore, Richard Dobson, Ammar Al-Chalabi, Daniel Bean, and Alfredo Iacoangeli,#

Disease models

- (d55) **Sleep and orexinergic pathway alterations in mice models of amyotrophic lateral sclerosis**
Simon J. GUILLOT *, Luc DUPUIS and Matei BOLBOREA
- (d56) **Blocking the $\beta 6/\beta 7$ loop epitope of misfolded SOD1 strongly delays disease onset and extends survival in a mouse model of ALS**
Shamchal Bakavayev, Zeev Barak, Adrian Israelson, Stanislav Engel*
- (d57) **Subcommissural organ-spondin-derived peptide (NX210c) improves motor function and prolongs survival in the SOD1G93A mouse model of ALS**
Sighild Lemarchant*, Liam Beckett, Irina Belaya, Nathalie Delétage, Jaan Korpikoski, Katja M. Kanninen, Merja H. Voutilainen, Yann Godfrin
- (d58) **Blocking the pathogenic $\beta 6/\beta 7$ -loop epitope of misfolded SOD1: a strategy for ALS disease treatment**
Shamchal Bakavayev*, Alexandra Stavsky, Adrian Israelson and Stas Engel
- (d59) **Comparison of neuromuscular junction pathology in four mouse models of spinal muscular atrophy indicates distinct patterns of selective vulnerability**
Victoria Zimmel, Irene Mei, Eva Hedlund, Lyndsay Murray
- (d60) **Multi-omics from hiPSC-derived motor neurons and patient biopsies identifies mutational signatures and potential transcriptional biomarkers for ALS**
Alberto Catanese, Medhanie Melaw
- (d61) **New approach based on synergic stimulation of cell membrane receptors targeting muscle tissue for ALS treatment**
Ana Rodríguez-Romano, Laura Moreno-Martinez, Juan Francisco Vázquez Costa, Rosario Osta, Patricia Rico*

- (d62) **A novel RT-QuIC method for prion-like SOD1 aggregation associated with ALS pathogenesis**
Laura P. Leykam*, Thomas Brännström, Peter M. Andersen, Per Zetterström
- (d63) **Modelling cortical changes in human C9ORF72-ALS brain organoids**
Astrid T van der Geest*, Tijana Ljubikj, Renata Sá, Svetlana Pasteuning, Daniëlle Vonk, Jasmijn Hundscheid, Marthe Kaal, Edwin van Oosten, Femke van Kalken, Leonard H van den Berg, Jan H Veldink, Onur Basak, R Jeroen Pasterkamp
- (d64) **Characterization of macrophage migration inhibitory factor as a therapeutic target for amyotrophic lateral sclerosis**
Leenor Alfahel*, Adrian Israelson
- (d65) **Investigating sporadic ALS using hiPSC-derived cells**
Lisha Ye*, Katarina Dittlau, Philip Van Damme, and Ludo Van Den Bosch,
- (d66) **Integrated multi-omics approach reveals ALS mutation-independent synaptic dysfunction in hiPSC-derived motor neurons**
Sandeep Rajkumar*, Tobias M. Böckers, Alberto Catanese
- (d67) **Y526 phosphorylation of FUS in ALS and FTD**
Helena Motaln*, Urša Čerček, Anand Goswami, Boris Rogelj
- (d68) **The p97-Nploc4 ATPase complex plays a role in muscle atrophy during cancer and amyotrophic lateral sclerosis**
Andrea David Re Cecconi, Mara Barone, Simona Gaspari, Massimo Tortarolo, Caterina Bendotti, Luca Porcu, Giulia Terribile and Rosanna Piccirillo*
- (d69) **C21orf2 mutations found in ALS disrupt primary cilia function**
Mathias De Decker *, Pavol Zelina, Thomas G Moens, Kristel Eggermont, Matthieu Moisse, Jan H. Veldink, Ludo Van Den Bosch, R. Jeroen Pasterkamp, Philip Van Damme
- (d70) **Combined epigenetic drugs elicit neuroprotective effect on sex dimorphic features in ALS mice**
Oluwamolakun Bankole*, Ilaria Scambi, Edoardo Parrella, Matilde Muccilli, Roberta Bonafede, Ermanna Turano, Marina Pizzi, Raffaella Mariotti
- (d71) **Inhibition of class I histone deacetylases ameliorates TDP-43 pathology in experimental models of ALS**
Serena Scozzari *, Eliana Sammali, Laura Pasetto, Stefano Fabrizio Columbro, Giovanni De Marco, Andrea Calvo, Valentina Bonetto
- (d72) **Cytoplasmic dynein defects cause reduced muscle strength and motor coordination, aberrant neuromuscular junction formation and TDP-43 mislocalisation**
Eleni Christoforidou†*, Fabio Simoes†, Luc Dupuis, Majid Hafezparast
- (d73) **Mapping PDH1-mediated neuroprotection in mutant SOD1 ALS mice at single-cell resolution**
Christine Germeys*&, Tijs Vandoorne&, Kristofer Davie, Suresh Poovathingal, Matthieu Moisse, Annelies Quaegebeur, Annerieke Sierksma, Katrien De Bock, Peter Carmeliet, Philip Van Damme, and Ludo Van Den Bosch
- (d74) **Glycogen modulates lifespan in a mouse model of amyotrophic lateral sclerosis**
M. Kathryn Brewer#, Pascual Torres##, Victòria Ayala, Manuel Portero-Otin, Reinald Pamplona, Pol Andrés-Benito, Isidro Ferrer, Joan J. Guinovart, Jordi Duran

- (d75) **Dysregulation of spinal interneuron subpopulations in the SOD1G93A ALS mouse model**
Roser Montañana-Rosell*, Raghavendra Selvan, Pablo Hernández-Varas, Dana B. Ahlmark, Jan M. Kaminski, Ole Kiehn, Ilary Allodi
- (d76) **An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD**
Claudia S. Bauer, Rebecca N. Cohen, Francesca Sironi, Matthew R. Livesey, Thomas H. Gillingwater, J Robin Highley, Daniel J. Fillingham, Emma F. Smith, Andrew J. Grierson, Caterina Bendotti, and Kurt J. De Vos*
- (d77) **Evaluation of M102, a dual NRF2 and HSF1 activator, as a Novel Therapeutic in Amyotrophic Lateral Sclerosis (ALS)**
Amy Keerie*, Shivani Suresh, Scott McKinnon, Dr Khoa Pham, Isaac Kirkland, Dr Ning Shan, Professor Dame Pamela Shaw, Dr Richard Mead
- (d78) **Peroxisomal lipid synthesis can be a disease-modifier factor in motor neurons from ALS patients**
Laia Fontdevila*, Omar Ramirez-Núñez, Victòria Ayala, Ricardo Romero-Guevara, Isidro Ferrer, Pol Andrés-Benito, Mònica Povedano, Pascual Torres, Reinald Pamplona, Manuel Portero-Otin
- (d79) **Insights for the identification of a molecular signature for ALS exploiting integrated miRNA profiling of iPSC-derived motor neurons and exosomes**
Mafalda Rizzuti *, Valentina Melzi, Delia Gagliardi, Megi Meneri, Pegah Masrori, Nicole Hersmus, Koen Poesen, Martina Locatelli, Nereo Bresolin, Giacomo Pietro Comi, Philip Van Damme, Monica Nizzardo, Stefania Corti
- (d80) **Synaptic degeneration is P53 independent in scenarios of disease, injury and development in mice**
Alannah J Mole*, Lyndsay M Murray
- (d81) **Convergent pathomechanisms underlying selective death of motoneurons in ALS using patients-derived iPSCs**
Amr Aly*, Tobias M. Böckers, Alberto Catanese
- (d82) **Using optogenetics to model activity-dependent neurodegeneration in amyotrophic lateral sclerosis**
Lucy Farrimond*, Ruxandra Dafinca, Colin Akerman, Kevin Talbot
- (d83) **Misfolded SOD1 aggregates are shaped by disease associated mutations and their microenvironment**
Nordström U.*, Lang L., Ekhtiari Bidhendi E., Zetterström P., Oliveberg M., Danielsson J., Andersen P. M., Marklund S. L.*
- (d84) **Ghrelin-based therapies for ALS – understanding mechanisms of action**
James Alexander Gray*, Gayle Doherty
- (d85) **Investigating impaired methylglyoxal detoxification as a potential mechanism of astrocyte toxicity in Amyotrophic Lateral Sclerosis (ALS/MND)**
Billie Ward*, Dr Scott Allen, Dr Richard Mead
- (d86) **Aging-dependent activity impairments of human C9orf72-mutant motor neurons are accompanied by aberrant transcriptional programs**
Daniel Sommer*, Alberto Catanese, Tobias M. Boeckers

- (d87) **RIPK1 is elevated in ALS patient spinal cords and RIPK1 kinase inhibition delays ALS disease progression in the SOD1G93A mouse model**
Matija Zelic, Fabrizio Pontarelli, Michael LaMorte, Tracie Treleaven, Emma McGuirk, Yi Ren, Fen Huang, Jim Dodge, Nellwyn Hagan, Nazem Atassi, Timothy R. Hammond, Dimitry Ofengeim. Non-author presenting: Roopali Gandhi Sanofi
- (d88) **Muscle stem cell and neuromuscular junction crosstalk in an ALS animal model**
Amaia Elicegui*, Oihane Pikatza-Menoio, Laura Moreno-Martinez, Rosario Osta, Ander Izeta, Adolfo López de Munain, Sonia Alonso-Martín
- (d89) **Differential effects following the cannabinoid CB1 or CB2 receptor activation in a frontotemporal dementia-related TDP-43 mouse model**
Irene Santos-García, Laura García Toscano, Claudia Gonzalo-Consuegra, Raquel Martín Vaquero, Marta Gómez Almería, Carmen Rodríguez Cueto, Javier Fernández Ruiz, Eva de Lago*
- (d90) **The role of FUS in axonal translation for motor neuron homeostasis and degeneration**
Tessa Robberechts*, Sandrine Da Cruz
- (d91) **Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis**
Thibaut Burg*, Elisabeth Rossaert, Matthieu Moisse, Philip Van Damme, and Ludo Van Den Bosch
- (d92) **Human iPSC-derived motor neurons and spinal cord organoids to model C9orf72 ALS**
Monica Nizzardo, Michela Taiana, Noemi Galli, Mafalda Rizzuti, Margherita Bersani, Fabio Biella, Alessia Anastasia, Linda Ottoboni, Giacomo Comi, and Stefania Corti
- (d93) **Characterisation of TDP-43 expression in the Thy1-hTDP-43 ALS mouse model**
Megan Shand*, Abrar Alhindi, Dinja van der Hoorn, Yu-Ting Huang, Kiterie M E Faller, Thomas H Gillingwater, Helena Chaytow
- (d94) **3D Bioprinting as a promising approach for the differentiation of stem cells in the study of ALS**
Eveljn Scarian*, Matteo Bordoni, Valentina Fantini, Emanuela Jacchetti, Stephana Carelli, Cristina Cereda, Orietta Pansarasa
- (d95) **Assessing impaired mitostasis as common denominator underlying motor neuron degeneration in amyotrophic lateral sclerosis**
Silke Vanderhaeghe *, Marc Fivaz, Jovan Prerad, Katrien Princen, Philip Van Damme, Pieter Vermeersch, Gerard Griffioen °, Ludo Van Den Bosch °
- (d96) **Characterization of motor neuron organoids derived from sALS patients**
Matteo Bordoni, Eveljn Scarian, Maria Garofalo, Letizia Messa, Emanuela Jacchetti, Manuela Teresa Raimondi, Stephana Carelli, Cristina Cereda, Stella Gagliardi, Orietta Pansarasa*
- (d97) **Assessing FUS liquid-liquid phase separation and toxicity in Drosophila ALS models**
Thomas G Moens*, Wendy Scheveneels, Jie Wang, Simon Alberti, Ludo Van Den Bosch
- (d98) **High-throughput drug screening to identify modifiers of TDP-43 protein aggregation**
Alessandra Cardinali*, James Longden, James Cooper, Suvankar Pal, Bhuvaneish T Selvaraj, Giles Hardingham, Neil Carragher, Siddharthan Chandran

- (d99) **Characterisation of NMJ pathology in the Thy1-hTDP-43 ALS mouse model**
Abrar Alhindi*, Megan Shand, Dinja van der Hoorn, Yu-Tin Huang, Kiterie ME Faller, Ross Jones, Thomas H Gillingwater, Helena Chaytow
- (d100) **Crosstalk of TDP-43 and Optineurin in myeloid cells**
Nikolina Prtenjača*, Matea Rob, Josip Peradinović, Marija Marošević, Emanuele Buratti, Ivana Munitić
- (d101) **Rescuing locomotor deficits in an ALS mouse model by Extended Synaptotagmin 1 (ESYT1) overexpression**
Santiago Mora*, Rasmus von Huth-Friis; Anna Stuckert; Gith Noes-Holt; Raghavendra Selvan; Andreas Toft Sørensen; Ole Kiehn; Ilary Allodi
- (d102) **Dissecting the role of microglia in C9ORF72 ALS using brain organoids**
Tijana Ljubikj*, Astrid T van der Geest, Renata Vieira de Sá, Nils Bessler, Daniëlle Vonk, Xynthia Oetelaar, Vanessa Donega, R. Jeroen Pasterkamp
- (d103) **Characterisation of a Rat Model of ALS8**
Brenda Murage*, Rachel Kline, Thomas Wishart, Mandy Jackson, Paul Skehel
- (d104) **Sigma-1 receptor is a pharmacological target to promote neuroprotection in the SOD1G93A ALS mice**
Núria Gaja-Capdevila*, Neus Hernández, Xavier Navarro, Mireia Herrando-Grabulosa
- (d105) **Modulation of VDAC promotes motoneuron survival after brachial plexus injury**
Carla Badia-Puiggalí*, Neus Hernández, Mireia Herrando-Grabulosa, Xavier Navarro
- (d106) **Metabolic switch as a tool to unmask mitochondrial failure in MEFs carrying TARDBP mutations**
Chiara Rossi, Abraham Acevedo-Arozena, Pascual Torres, Anna Fernández, Míriam Ceron-Codorniu, Pol Andrés-Benito, Mònica Povedano, Isidro Ferrer, Reinald Pamplona, Manuel Portero-Otin
- (d107) **Amyotrophic lateral sclerosis at single cell resolution**
Christoph Schweingruber*, Jik Nijssen, Jonas Mechttersheimer, Stefan Reber, Michaela Keuper, Julio Aguila Benitez, Martin Jastroch, Marc-David Ruepp, Eva Hedlund
- (d108) **Retrograde tracing of monosynaptic inputs to MCH+ cells by mutant rabies virus in SOD1G93A ALS murine model**
Scekic-Zahirovic Jelena*, Wiesner Diana, Antonucci Stefano, Londo Amela, Yartas Gizem, Bayer David, & Roselli Francesco,
- (d109) **Longitudinal in vitro study for ALS-like phenotypes in hiPSC-derived motor neurons**
Salim Benlefki, João Sousa*, Irene Mei, Eva Hedlund
- (d110) **Modelling the human neuromuscular junction in vitro**
Irene Mei, Silvia Gómez*, Christoph Schweingruber, Alexandra Bartee, Jik Nijssen, Gill Pollmeier, Mélanie Leboeuf, Eva Hedlund
- (d111) **Resistant and vulnerable motor neurons show unique temporal gene regulation in SOD1G93A ALS**
Irene Mei*, Susanne Nichterwitz, Jik Nijssen, Christoph Schweingruber, Eva Hedlund
- (d112) **Investigating the upregulation of adenosine deaminase in ALS astrocytes**
Benjamin Hall*, Scott Allen

- (d113) **Understanding Disease Trajectory in Amyotrophic Lateral Sclerosis**
Ahmad Al Khleifat
- (d114) **Reduction of oxidized phospholipids or misfolded protein aggregates by AAV-VectAbs in ALS pre-clinical models**
Marina Sogorb-Gonzalez*, Svetlana Pasteuning, Wouter Pos, Menno Spits, Andreia Duarte, Roland van Dijk, Martino Bohne, Sander van Deventer, Pavlina Konstantinova
- (d115) **MicroRNA dysregulation as a driver of WNT activation and motor neuron degeneration in ALS**
Seema C. Namboori, Ammarah Tariq, Catherine Blaker, Christine Flaxman, Andrew Randall, Alessandro Rosa, Lawrence W. Stanton, Akshay Bhinge#

Session 2 – Thursday

Neuroinflammation

- (e116) **Increased cleaved GSDMD expression in white matter microglia is associated with neuronal loss in the ALS motor cortex**
Evelien Van Schoor*, Simona Ospitalieri, Sebastiaan Moonen, Sandra O. Tomé, Alicja Ronisz, Orkun Ok, Lieselot Dedeene, Jochen Weishaupt, Albert C. Ludolph, Philip Van Damme, Ludo Van Den Bosch, Dietmar R. Thal
- (e117) **Therapeutic potential of Naringenin on primary microglia derived from mutant G93A-SOD1 mice**
Nadine Thau-Habermann N*, Thomas Gschwendtberger, Tilman Riesmeier and Susanne Petri
- (e118) **A novel proposed panel of inflammatory and redox genes as biomarkers in amyotrophic lateral sclerosis**
Ilaria Giovannelli*, Laura Chapman, Ana Rojo, Antonio Cuadrado, Martin R Turner, Andrea Malaspina, Janine Kirby and Pamela J Shaw
- (e119) **TDP-43 Immunotherapy decreases neuropathology and confers neuroprotection through microglial engagement in mouse models of ALS/FTD**
Elodie Chevalier*, Tariq Afroz, Mickael Audrain, Anne-Laure Egesipe, Lorène Mottier, Manuela Neumann, Romain Ollier, Kasia Piorkowska, Christopher Dumayne, Valerie Eligert, Oskar Adolfsson, Sílvia Porta, Virginia M.-Y. Lee, Andrea Pfeifer, Marie Kosco-Vilbois, Tamara Seredenina
- (e120) **Investigating the microglial role of ALS/FTD-associated gene TANK-binding kinase 1**
Uroosa Chughtai*, Daniel Cabezas De La Fuente, Raja Nirujogi, Dario Alessi, Gaynor Smith, Meng Li, Owen Peters
- (e121) **A multicentric approach to monocyte alterations in ALS**
Sarah J. Brockmann, Pegah Masrori, Matthieu Ribon, Divisha Bhatia, David Brenner, Maria del Mar Amador, Adèle Hesters, Albert C. Ludolph, Karin M. Danzer, François Salachas*, Philip Van Damme*, Séverine Boillée*, Jochen H. Weishaupt*
- (e122) **The role of C3 inhibition in an iPSC NMJ model of neuroinflammation**
Scott Baver*, Virginia Smith, Yan Li, David Eyerman, Ashley Robertson, Leticia Lenkiu, Heather Cannon, Daisy Martinez, Hannah Hanson, James J. Hickman

(e123) **The interferon signalling pathway as potential therapeutic target in amyotrophic lateral sclerosis and frontotemporal dementia – a systematic review and meta-analysis**
Fergal M. Waldron*, Olivia M. Rifai and Jenna M. Gregory

(e124) **Microglial engulfment of ALS synapses**
Zsofia I Laszlo, Michael Daniels, Chris Henstridge

Neuropsychology

(f125) **Factors affecting anticipatory grief: Do severity of the disease and behavioural changes predict anticipatory grief in family carers of MND?**
Ana Paula Trucco*, Mizanur Khondoker, Naoko Kishita, Tamara Backhouse, Eneida Mioshi

(f126) **Loneliness is associated with behavioural changes and fronto-parietal networks in ALS**
Monica Consonni*, Eleonora Dalla Bella, Enrica Bersano, Veronica Faltracco, Alessandra Telesca, Elena Ilaria Giuga, Anna Nigri, Maria Grazia Bruzzone, Giuseppe Lauria

(f127) **The Sustained Attention to Response Task evokes sensorimotor beta ERD/ERS and enables quantification of motor and cognitive pathophysiology**
Roisin McMackin*, Stefan Dukic, Eileen R Giglia, Marjorie Metzger, Vlad Sirenko, Saroj Bista, Matthew Mitchell, Emmet Costello, Marta Pinto-Grau, Antonio Fasano, Teresa Buxo, Richard Reilly, Niall Pender, Orla Hardiman, Bahman Nasserolelami

(f128) **Caregiving burden in Amyotrophic Lateral Sclerosis (ALS): Association with cognitive changes and emotional distress**
Greta García-Escobar*, Bernat Bertran-Recasens, Sandra Blavi-Pujol, Miguel Ángel Rubio

(f129) **Altered gaze control during emotional face exploration in Amyotrophic lateral sclerosis**
F. Nanning, K. Braune, I. Uttner, A. C. Ludolph, M. Gorges#, D. Lulé# *#contributed equally

(f130) **Reliability and validity of the remote administration of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS)**
Debbie Gray*, Rosie Leslie, Emily Mayberry, Judith Newton, Suvankar Pal, Siddharthan Chandran, CARE-MND Consortium, Luke Williams, Sarah MacPherson, Sharon Abrahams

(f131) **Quality of life in adult patients with spinal muscular atrophy**
Aleksa Palibrk*, Vanja Virić, Ivo Božović, Stojan Perić, Ivana Basta, Zorica Stević

(f132) **Assessing mental capacity in people with MND: What healthcare professionals think, know and do**
Debbie Gray*, Luke Williams, Sarah MacPherson, Sharon Abrahams

(f133) **Treatment management and quality of life in ALS patients**
Andrea Lizio*, Marco Salivetto, Luca Diamanti, Valeria Sansone, Christian Lunetta

(f134) **Holistic Assessment of Non-Motor Symptoms for People with Motor Neuron Disease (NMS-MND)**
Emily Beswick*, Deborah Forbes, Rachel Dakin, Judith Newton, Alan Carson, Sharon Abrahams, Siddharthan Chandran, Suvankar Pal

Neuropathology

- (g135) **TDP-43 aggregates accumulate in the gastrointestinal tract prior to symptom onset in amyotrophic lateral sclerosis**
Samuel B. Pattle, Judi O'Shaughnessy, Olivia M. Rifai, Judith Pate, Fergal M. Waldron and Jenna M. Gregory*
- (g136) **Alternative counterstains improve detection and digital analysis of chromogenic BaseScope™ in situ hybridisation signal in human post-mortem tissue**
Judi O'Shaughnessy*, Olivia M. Rifai, & Jenna M. Gregory
- (g137) **Cytoplasmic mislocalization and aggregation of TDP-43 in brains of ALS and FTD patients**
Laura Expósito-Blázquez*, Daniel Borrego-Hernández, María del Carmen Herrero-Manso, Pilar Cordero-Vázquez, Alberto Villarejo-Galende, Sara Llamas-Velasco, Marta González-Sánchez, Miguel Ángel Martín-Casanueva, Jesús Esteban-Pérez, Alberto Rábano-Gutiérrez and Alberto García-Redondo
- (g138) **High-resolution imaging of synapse density in ALS brain and its association with clinical presentation**
Anna Sanchez Avila *, Tara Spires-Jones, Thomas Gillingwater, Christopher Henstridge
- (g139) **Rapamycin reverts TDP-43 splicing defects and oxidative stress-induced alterations in a human in vitro model of TDP-43 proteinopathy**
Casiraghi Valeria, Colombrita Claudia, Santangelo Serena, Milone Ilaria, Sorce Marta, Silani Vincenzo, Ratti Antonia

Clinical

- (h140) **Faculty Development in a Multidisciplinary ALS Clinic**
Madhu Soni, MD, FAAN*
- (h141) **UPDATED: The United States National Amyotrophic Lateral Sclerosis (ALS) Registry Advances Research Domestically and Internationally**
Paul Mehta, MD, Ted Larson, MS, Kevin Horton, DrPH
- (h142) **Robotic assessment with artificial intelligence in the evaluation of ALS disease progression**
Andrea Lizio*, Marco Salivetto, Silvia Bolognini, Jacopo Casiraghi, Valeria Sansone, Stefano Regondi, Christian Lunetta
- (h143) **Assessment of the upper motor neuron in ALS using Combined Patellar Tendon Reflex-MEP to Lower Limb: a monocentric cohort**
Annaïck Desmaison, André Truffert, Bruno Pereira, Jean-Philippe Camdessanché, Nathalie Guy
- (h144) **Validation of the DYALS (dysphagia in amyotrophic lateral sclerosis) questionnaire for the evaluation of dysphagia in ALS patients**
Luca Diamanti*, Paola Borrelli, Raffaele Dubbioso, Margherita Capasso, Claudia Morelli, Christian Lunetta, Antonio Petrucci, Gabriele Mora, Paolo Volanti, Maurizio Inghilleri, Lucio Tremolizzo, Jessica Mandrioli, Letizia Mazzini, Marcella Vedovello, Gabriele Siciliano, Massimiliano Filosto, Sabrina Matà, Cristina Montomoli, DYALS Study Group

- (h145) **Impact of ALS subtypes on disease progression: A continuous temporal multivariate approach**
Juliette ORTHOLAND, Igor KOVAL, Pierre-François PRADAT, Sophie TEZENAS DU MONTCEL, Stanley DURRLEMAN
- (h146) **The value of the El Escorial Criteria (EEC)**
Nathalie Braun*, Adriaan D De Jongh, Ruben P A van Eijk, Leonard H van den Berg, Hardiman Orla, Philip Van Damme, Adriano Chio, Markus Weber
- (h147) **Serum Chloride is a low cost marker of respiratory failure in Amyotrophic Lateral Sclerosis**
Umberto Manera*, Maurizio Grassano, Maria Claudia Torrieri, Antonio Canosa, Rosario Vasta, Francesca Palumbo, Paolo Cugno, Enrico Matteoni, Sara Cabras, Francesca Di Pede, Filippo De Mattei, Cristina Moglia, Andrea Calvo, Adriano Chiò
- (h148) **Simulating motor neuron degeneration and reinnervation in motor neuron disease based on surface-electromyography recorded single motor unit potentials**
Boudewijn T.H.M. Sleutjes*, Diederik J.L. Stikvoort Garcia, H. Stephan Goedee, Leonard H. van den Berg
- (h149) **Characterizing Hospitalization as an Outcome Measure in ALS Clinical Trials**
Zachary Simmons, Ammar Al-Chalabi, Jinsy Andrews, Adriano Chio, Phillippe Corcia, Philippe Couratier, Merit Cudkowicz, Mamede de Carvalho, Angela Genge, Orla Hardiman, Terry Heiman-Patterson, Robert Henderson, Caroline Ingre, Wendy Johnston, Albert Ludolph, Nicholas Maragakis, Timothy Miller Jesus Mora Pardina, Susanne Petri, Jeremy Shefner, Leonard van den Berg, Lorne Zinman, Stuart Kupfer, Fady Malik, Lisa Meng, Jenny Wei, Andrew Wolff, *Stacy Rudnicki
- (h150) **Utility of the spirometry, arterial blood gas analysis and nocturnal oximetry in the respiratory outcome of motor neuron disease**
Paride Schito*, Tommaso Russo, George Cremona, Andrea Tettamanti, Luca Bresciani, Gasperotti Filippo, Yuri Matteo Falzone, Mauro Comola,, Angelo Quattrini, Massimo Filippi, Nilo Riva
- (h151) **Repeated training improves administration of the ALSFRS-R**
Jenny Hamilton, Praveena Mohan, Gale Kittle, Jeremy Shefner*
- (h152) **Baseline Speech Assessment and Vital Capacity Measured Remotely and in Clinic in the HEALEY ALS Platform Trial**
Jeremy Shefner, Sabrina Paganoni, Merit Cudkowicz, James Berry, Shira Hahn, Gabriela Stegmann, Julie Liss, Visar Berisha, Eric Macklin on behalf of the HEALEY ALS Platform Trial Study Group
- (h153) **Autonomy and self-determination. Are we respecting them in our patients?**
J.F. Vázquez Costa, A Martínez*
- (h154) **Prognostic Modelling of Motor Neuron Disease in Scotland**
Danielle Leighton*, Judith Newton, Shuna Colville,, Laura Stephenson, Samuel Leighton, Emily Beswick,, Michaela Johnson, Juan Larraz,, Javier Carod-Artal, Richard Davenport, Callum Duncan, George Gorrie, Ian Morrison, Robert Swingler, Siddharthan Chandran, Suvankar Pal, and the CARE-MND Consortium

- (h155) **Phenotypic Characterisation and Genetic Epidemiology of Motor Neuron Disease in Scotland**
Danielle Leighton, Judith Newton, Morad Ansari, Elaine Cleary, Shuna Colville, Laura Stephenson, Emily Beswick, Micheala Johnson, Juan Larraz, Javier Carod-Artal, Callum Duncan, Richard Davenport, George Gorrie, Ian Morrison, Sharon Abrahams, Robert Swingler, Ian J Deary, Mary Porteous, Siddharthan Chandran, Suvankar Pal, and the CARE-MND Consortium
- (h156) **Coexistence of CASQ1-related myopathy and Amyotrophic Lateral Sclerosis in an Italian patient: a case description**
Lorenzo Fontanelli*, Francesca Bianchi, Lucrezia Becattini, Raffaella Brugnioni, Gabriele Siciliano
- (h157) **Capillaroscopic alterations in Amyotrophic Lateral Sclerosis**
Abdelilah Assialioui, Carla Marco-pascual, Raul Dominguez, Carla Marco-cazcarra, Esther Catena, Xavier Juanola, Isidre Ferrer, Monica Povedano
- (h158) **Altered Angiopoietin like proteins correlate with lipid metabolism in ALS**
Sruthi Sankari Krishnamurthy*, Diana Wiesner, Veronika-Felicitas Klose, Gizem Yartas, Dagmar Schattauer, Maximilian Wiesenfarth, Kristina Mayer, Albert Ludolph, Luc Dupuis, Johannes Dorst, Francesco Roselli
- (h159) **Lived Experience of Persons with Amyotrophic Lateral Sclerosis Who Are Participating in a Clinical Trial**
Vanessa Bertone*, Mathias Couillard, Dolores Bertone, Helen Fong, Smita Patel, Sean Turner, Angela Genge
- (h160) **Bringing health care closer to patients – two years of the home care ALS programme in Slovenia**
Blaž Koritnik*, Patricija Kranjc, Stanka Ristič Kovačič, Mojca Lukša, Maša Vučina Ojsteršek, Marko Kučan, Sara Kadenšek, Eva Žitnik, Janez Zidar
- (h161) **A systematic review of wearable technologies for evaluating disease progression in motor neuron disease**
Emily Beswick*, Thomas Fawcett, Zack Hassan, Deborah Forbes, Rachel Dakin, Judith Newton, Sharon Abrahams, Alan Carson, Siddharthan Chandran, David Perry, Suvankar Pal
- (h162) **Genetic-environment interactions to discover novel risk factor in ALS: a proof-of-concept application in a population-based register**
Maurizio Grassano*, Stefano Callegaro, Rosario Vasta, Umberto Manera, Federico Casale, Antonio Canosa, Cristina Moglia, Bryan J. Traynor, Andrea Calvo, Adriano Chiò
- (h163) **ALS incidence by geographical area in England**
Opie-Martin, S., Bredin, A., Ossher, L., Chiwera, T, Talbot, K., Al-Chalabi, A.
- (h164) **Identification of ALS slow progressors through the Emilia Romagna regional registry: a possible target population for biomarker studies**
Elisabetta Zucchi*, Ilaria Martinelli, Cecilia Simonini, Giulia Gianferrari, Nicola Fini, Maria Caputo, Andrea Ghezzi, Prof. Jessica Mandrioli
- (h165) **A systematic review of digital technology to evaluate speech dysfunction in amyotrophic lateral sclerosis.**
Molly Bowden & Emily Beswick*, David Perry, Alice Smith, Oliver Watts, Alex Symonds, Judy Newton, Rachel Dakin, Siddharthan Chandran, Suvankar Pal

- (h166) **Use and subjective experience of the impact of a motor-assisted movement exerciser in people with ALS: a multicenter observational study**
André Maier*, Marcel Gaudlitz, Torsten Grehl, Ute Weyen, Robert Steinbach, Julian Großkreutz, Annekatriin Rödiger, Jan Christoph Koch, Teresa Lengenfeld, Patrick Weydt, René Günther, Joachim Wolf, Petra Baum, Moritz Metelmann, Johannes Dorst, Albert Christian Ludolph, Dagmar Kettemann, Jenny Norden, Ruhan Yasemin Koc, Bertram Walter, Barbara Hildebrandt, Christoph Münch, Thomas Meyer, Susanne Spittel
- (h167) **User expectation and user experience of a robotic arm in people with ALS: a multicenter observational study**
Susanne Spittel*, Ute Weyen, Torsten Grehl, Patrick Weydt, Robert Steinbach, Susanne Petri, Petra Baum, Moritz Metelmann, Elena Schlapakow, Anne-Dörte Sperfeld, Dagmar Kettemann, Jenny Norden, Annekathrin Rödiger, Benjamin Ilse, Maren Freigang, Julian Großkreutz, Yasemin Koc, Bertram Walter, Christoph Münch, Thomas Meyer, André Maier
- (h168) **Socioeconomic status and ALS**
Ali Shojaie, Ahmad Al Khleifat, Sarah Opie-Martin, Haniah Habash Bailey, Sarah Garrahy, Nigel Leigh, Ammar Al-Chalabi
- (h169) **Timing of NIV initiation in patients with ALS based on forced vital capacity: a retrospective propensity score matched analysis**
Fouke Ombelet*, Bart Vrijisen, Nikita Lamaire, Hilde Beyens, Goedele Couwelier, Sien Maebe, Petra Tilkin, Ann D'Hondt, Leonard van den Berg, Ruben van Eijk, Dries Testelmans, Bertien Buyse, Philip Van Damme
- (h170) **Withdrawal of life-sustaining treatment in ALS patients: a Multicenter Italian Survey**
Cristina Moglia*, Francesca Palumbo, Veronese Simone, MND Italian Study Group, Andrea Calvo
- (h171) **Evaluation of the nation-wide implementation of ALS Home monitoring & Coaching: an e-health innovation for personalized care for patients with ALS**
Anita Beelen*, Manon Dontje, Esther Kruitwagen-van Reenen, Evaline van Wijk, Erwin Baars, Anne Visser-Meily, and on behalf of the Study Group ALS Home monitoring & Coaching
- (h172) **Effect of age on interventions and survival in people with motor neuron disease in Scotland**
Alexander Christides, Alexander L Symonds, Micheala Johnson, Emily Beswick, Judith Newton, Richard Davenport, Callum Duncan, Ian Morrison, Javier Carod Artal, George Gorrie, Robert Swingler, Siddharthan Chandran, and Suvankar Pal on behalf of the CARE-MND Consortium
- (h173) **Epidemiology of MND in Czech Republic**
Khazaal M, Kara S, Jarkovsky J, Slachtova L
- (h174) **Validation of ENCALs ALS survival model on US Population**
Alex Berger, Ruben van Eijk, Ervin Sinani, Alexander V. Sherman
- (h175) **Initial results of the REVEALS study: Registry of Endpoints and Validated Experiences in ALS**
Murray D, Rooney J, Chio A, Al-Chalabi A, McDermott C, Van Damme , Van Den Berg L, Meldrum D, Hardiman O
- (j201) **A cross-sectional study to evaluate the determinants of Quality of Life in patients affected by Amyotrophic Lateral Sclerosis**
Lucia Catherine Greco, Andrea Lizio, Jacopo Casiraghi, Valeria Sansone, Stefano Regondi, Christian Lunetta

Clinical trials

- (i177) **Statistical Model of the Relationship of Neurofilament with Clinical Function in the VALOR Phase 3 Study of Tofersen in Adults with SOD1-ALS**
Jonathan D. Glass*, Timothy Miller, Merit Cudkowicz, Philip van Damme, Stephanie Fradette, Danielle Graham, Manjit McNeill, Susie Sinks, Peng Sun, Luan Lin
- (i178) **RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial**
Elisabetta Pupillo*, Ettore Beghi, Elisa Bianchi, Valentina Bonetto, Caterina Bendotti, Letizia Mazzini and RNS Study group.
- (i179) **Plasma biomarkers of microbial translocation are modulated in ALS patients clinically responsive to NP001**
Michael McGrath*, Rongzhen Zhang, Paige Bracci, Bruce Forrest, Ari Azhir
- (i180) **When estimating causal effects in amyotrophic lateral sclerosis (ALS) randomized clinical trials, start by defining causal estimands — not estimators**
Bind, Marie-Abele*; Macklin, Eric; Rubin, Donald
- (i181) **Efficacy and safety of RIPK1 inhibitor SAR443820 in adult participants with amyotrophic lateral sclerosis (ALS): The Himalaya phase 2 trial design**
Merit Cudkowicz, Jeremy Shefner, Leonard H. van den Berg, Angela Genge, Adriano Chio, Xiaoyu Jiang, Erik Wallstroem, Li Xiong*, Nazem Atassi
- (i182) **Preclinical evaluation of WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of C9orf72-associated ALS or FTD**
Yuanjing Liu, Amy Andreucci, Naoki Iwamoto, Yuan Yin, Hailin Yang, Fangjun Liu, Alexey Bulychev, Xiao Shelley Hu, Xuena Lin, Sarah Lamore, Saurabh Patil, Susovan Mohapatra, Erin Purcell-Estabrook, Kuldeep Singh, Kristin Taborn, Elena Dale, Chandra Vargeese
- (i183) **Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results**
Angela Genge*, MD, FRCPC, Gary L. Pattee, MD, Gen Sobue, MD, PhD, Philippe Couratier, MD, PhD, Daniel Selness, RN, BA, MBA, Sachin Bidani, M. Pharm, Manabu Hirai, MS, Takeshi Sakata, MS, Alejandro Salah, MD, PhD, MBA, BCMAS, Stephen Apple, MD
- (i184) **Phase 3, Open-Label, Safety Extension Study of Investigational Oral Edaravone Administered Over 96 Weeks in Patients with ALS (MT-1186-A03)**
Daniel Selness*, RN, BA, MBA, Manabu Hirai, MS, Takeshi Sakata, MS, Alejandro Salah, MD, PhD, MBA, BCMAS, Stephen Apple, MD
- (i185) **Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results**
Lahar Mehta*, Yuehui Wu, Jamie Timmons, Sabrina Paganoni, Merit E. Cudkowicz
- (i186) **Sudden Changes in the ALSFRS-R in Three ALS Trials**
Jeremy M. Shefner*, Stuart Kupfer, Fady I. Malik, Lisa Meng, Stacy Rudnicki, Andrew A Wolff, Jenny Wei
- (i187) **DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis**
Grace Mann*, Ruben P. A. van Eijk, Dale Zhang, Hazel J. Hunt, Leonard H. van den Berg

- (i188) **A composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)**
Ruben P.A. van Eijk*, Leonard H. van den Berg, Ying Lu
- (i189) **Developing a systematic framework to identify, evaluate and report evidence for drug selection in motor neuron disease clinical trials**
Charis Wong*, Alessandra Cardinali, Bhuvaneish T. Selvaraj, Rachel S Dakin, Neil Carragher, Suvankar Pal, Siddharthan Chandran, Malcolm Macleod on behalf of the ReLiSyR-MND group
- (i190) **The Impact of Diverse Therapeutic Targets and Treatment Modalities on Clinical Trial Design, Operations and Participation**
Richard Bennett*, Lucie Undus, Christopher Mason, Tomislav Babic
- (i191) **Design and Implementation of the Tofersen Early Access Program**
Jeannette N. Stankowski**, Danielle Rafferty, Kerisha Naidoo*, Peter Graham*, Stephanie Fradette, Thos Cochrane
- (i192) **First experience of the treatment with antisense nucleotide tofersen in ALS patient due to SOD1 mutation**
Egle Sukockiene*, Annemarie Hübers
- (i193) **Detectable Effect Cluster Analysis: A Novel Machine-Learning Subgroup Analysis Method for Drug Rescue**
Danielle Beaulieu, Mark Schactman, Albert A. Taylor, Jonavelle Cuerdo, and David L. Ennist
- (i194) **Factors Influencing Trial Participation in Motor Neuron Disease (FIT-Participation in MND)**
Emily Beswick*, Stella A Glasmacher, Rachel Dakin, Judith Newton, Alan Carson, Sharon Abrahams, Siddharthan Chandran, Suvankar Pal
- (i195) **Design of an international, phase 3, randomized, placebo-controlled trial with daily oral edaravone (FNP122) in ALS: the ADORE study**
Leonard van den Berg, Ruben Van Eijk, Ammar Al-Chalabi, Adriano Chio, Orla Hardiman, Chris McDermott, Mónica Povedano, Philip van Damme, Gabriela Bacchini, Cristina Tarragó, Mohammed Ezzeldin, and Nuria Albareda
- (i196) **ALS Phase 3 NurOwn Trial: Insight into the primary outcome through ENCALS modeled trajectories**
Namita Goyal, Jonathan Katz*, Nathan Staff, Jenny Li, Ralph Kern, Merit Cudkowicz, James Berry, Anthony Windebank, Robert Brown, Robert Miller, Matthew Burford, Bruno Boulanger, Munish Mehra, Revital Aricha, Yael Gothelf, Stacy Lindborg
- (i197) **Preliminary Biomarker Findings from the RESCUE-ALS Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS**
Steve Vucic PhD, DSc, FRACP, FAHMS, Northcott Chair of Neurology, Director Brain and Nerve Research Center; Parvathi Menon PhD, FRACP, Clinical Study Director and Clinical Senior Lecturer; William Huynh PhD, FRACP, Clinical Study Director and Neurologist; Colin Mahoney, PhD, MB, MRCPI, Clinician Scientist and Neurologist; Karen S. Ho, PhD MSc, Head, Translational Medicine, Austin Rynders, RN, Senior Director, Clinical Operations; Jacob Evan, Clinical Operations Manager; Jeremy Evan, PA-C, Clinical Operations Lead; Robert Glanzman, MD FAAN, Chief Medical Officer; Michael T. Hotchkin, Chief Development Officer; Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS, Bushel Chair of Neurology, Professor of Medicine, Central Clinical School and Co-Director, Discovery and Translation, Brain and Mind Centre

- (i198) **RESCUE-ALS Trial Results: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS**
 Steve Vucic PhD, DSc, FRACP, FAHMS, Northcott Chair of Neurology, Director Brain and Nerve Research Center; Parvathi Menon PhD, FRACP, Clinical Study Director and Clinical Senior Lecturer; William Huynh PhD, FRACP, Clinical Study Director and Neurologist; Colin Mahoney, PhD, MB, MRCPI, Clinician Scientist and Neurologist; Karen S. Ho, PhD MSc, Head, Translational Medicine; Austin Rynders, RN, Senior Director, Clinical Operations; Jacob Evan, Clinical Operations Manager; Jeremy Evan, PA-C, Clinical Operations Lead; Robert Glanzman, MD FAAN, Chief Medical Officer; Michael T. Hotchkin, Chief Development Officer; Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS, Bushel Chair of Neurology, Professor of Medicine, Central Clinical School and Co-Director, Discovery and Translation, Brain and Mind Centre
- (i199) **Evidence for a Potential Survival Benefit in ALS with CNM-Au8 Treatment: Interim Results from the RESCUE-ALS Trial Long-Term Open Label Extension**
 Steve Vucic PhD, DSc, FRACP, FAHMS, Parvathi Menon PhD, FRACP, William Huynh PhD, FRACP, Colin Mahoney, PhD, MB, MRCPI, Karen S. Ho, PhD MSc, Austin Rynders, RN, Jacob Evan, Jeremy Evan, PA-C, Robert Glanzman, MD FAAN, Michael T. Hotchkin, Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS
- (i200) **Interim ALS Specific Quality of Life Results from the Long-Term Open Label Extension of RESCUE-ALS, a Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS**
 Steve Vucic PhD, DSc, FRACP, FAHMS, Northcott Chair of Neurology, Director Brain and Nerve Research Center; Parvathi Menon PhD, FRACP, Clinical Study Director and Clinical Senior Lecturer; William Huynh PhD, FRACP, Clinical Study Director and Neurologist; Colin Mahoney, PhD, MB, MRCPI, Clinician Scientist and Neurologist; Karen S. Ho, PhD MSc, Head, Translational Medicine; Austin Rynders, RN, Senior Director, Clinical Operations; Jacob Evan, Clinical Operations Manager; Jeremy Evan, PA-C, Clinical Operations Lead; Robert Glanzman, MD FAAN, Chief Medical Officer; Michael T. Hotchkin, Chief Development Officer; Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS, Bushel Chair of Neurology, Professor of Medicine, Central Clinical School and Co-Director, Discovery and Translation, Brain and Mind Centre
- (i201) **Adapting an adaptive randomised control trial for motor neuron disease to covid-19 pressures**
 Amy Stenson, Rachel S Dakin, Judith Newton, Dawn Lyle, Christine Weaver, Jill Williamson, Suvankar Pal, Siddharthan Chandran

Clinical trials

- (i177) **Statistical Model of the Relationship of Neurofilament with Clinical Function in the VALOR Phase 3 Study of Tofersen in Adults with SOD1-ALS**
Jonathan D. Glass*, Timothy Miller, Merit Cudkowicz, Philip van Damme, Stephanie Fradette, Danielle Graham, Manjit McNeill, Susie Sinks, Peng Sun, Luan Lin
- (i178) **RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial**
Elisabetta Pupillo*, Ettore Beghi, Elisa Bianchi, Valentina Bonetto, Caterina Bendotti, Letizia Mazzini and RNS Study group.
- (i179) **Plasma biomarkers of microbial translocation are modulated in ALS patients clinically responsive to NP001**
Michael McGrath*, Rongzhen Zhang, Paige Bracci, Bruce Forrest, Ari Azhir
- (i180) **When estimating causal effects in amyotrophic lateral sclerosis (ALS) randomized clinical trials, start by defining causal estimands — not estimators**
Bind, Marie-Abele*; Macklin, Eric; Rubin, Donald
- (i181) **Efficacy and safety of RIPK1 inhibitor SAR443820 in adult participants with amyotrophic lateral sclerosis (ALS): The Himalaya phase 2 trial design**
Merit Cudkowicz, Jeremy Shefner, Leonard H. van den Berg, Angela Genge, Adriano Chio, Xiaoyu Jiang, Erik Wallstroem, Li Xiong*, Nazem Atassi
- (i182) **Preclinical evaluation of WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of C9orf72-associated ALS or FTD**
Yuanjing Liu, Amy Andreucci, Naoki Iwamoto, Yuan Yin, Hailin Yang, Fangjun Liu, Alexey Bulychev, Xiao Shelley Hu, Xuena Lin, Sarah Lamore, Saurabh Patil, Susovan Mohapatra, Erin Purcell-Estabrook, Kuldeep Singh, Kristin Taborn, Elena Dale, Chandra Vargeese
- (i183) **Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results**
Angela Genge*, MD, FRCPC, Gary L. Pattee, MD, Gen Sobue, MD, PhD, Philippe Couratier, MD, PhD, Daniel Selness, RN, BA, MBA, Sachin Bidani, M. Pharm, Manabu Hirai, MS, Takeshi Sakata, MS, Alejandro Salah, MD, PhD, MBA, BCMAS, Stephen Apple, MD
- (i184) **Phase 3, Open-Label, Safety Extension Study of Investigational Oral Edaravone Administered Over 96 Weeks in Patients with ALS (MT-1186-A03)**
Daniel Selness*, RN, BA, MBA, Manabu Hirai, MS, Takeshi Sakata, MS, Alejandro Salah, MD, PhD, MBA, BCMAS, Stephen Apple, MD
- (i185) **Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results**
Lahar Mehta*, Yuehui Wu, Jamie Timmons, Sabrina Paganoni, Merit E. Cudkowicz
- (i186) **Sudden Changes in the ALSFRS-R in Three ALS Trials**
Jeremy M. Shefner*, Stuart Kupfer, Fady I. Malik, Lisa Meng, Stacy Rudnicki, Andrew A Wolff, Jenny Wei
- (i187) **DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis**
Grace Mann*, Ruben P. A. van Eijk, Dale Zhang, Hazel J. Hunt, Leonard H. van den Berg

- (i188) **A composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)**
Ruben P.A. van Eijk*, Leonard H. van den Berg, Ying Lu
- (i189) **Developing a systematic framework to identify, evaluate and report evidence for drug selection in motor neuron disease clinical trials**
Charis Wong*, Alessandra Cardinali, Bhuvaneish T. Selvaraj, Rachel S Dakin, Neil Carragher, Suvankar Pal, Siddharthan Chandran, Malcolm Macleod on behalf of the ReLiSyR-MND group
- (i190) **The Impact of Diverse Therapeutic Targets and Treatment Modalities on Clinical Trial Design, Operations and Participation**
Richard Bennett*, Lucie Undus, Christopher Mason, Tomislav Babic
- (i191) **Design and Implementation of the Tofersen Early Access Program**
Jeannette N. Stankowski**, Danielle Rafferty, Kerisha Naidoo*, Peter Graham*, Stephanie Fradette, Thos Cochrane
- (i192) **First experience of the treatment with antisense nucleotide tofersen in ALS patient due to SOD1 mutation**
Egle Sukockiene*, Annemarie Hübers
- (i193) **Detectable Effect Cluster Analysis: A Novel Machine-Learning Subgroup Analysis Method for Drug Rescue**
Danielle Beaulieu, Mark Schactman, Albert A. Taylor, Jonavelle Cuerdo, and David L. Ennist
- (i194) **Factors Influencing Trial Participation in Motor Neuron Disease (FIT-Participation in MND)**
Emily Beswick*, Stella A Glasmacher, Rachel Dakin, Judith Newton, Alan Carson, Sharon Abrahams, Siddharthan Chandran, Suvankar Pal
- (i195) **Design of an international, phase 3, randomized, placebo-controlled trial with daily oral edaravone (FNP122) in ALS: the ADORE study**
Leonard van den Berg, Ruben Van Eijk, Ammar Al-Chalabi, Adriano Chio, Orla Hardiman, Chris McDermott, Mónica Povedano, Philip van Damme, Gabriela Bacchini, Cristina Tarragó, Mohammed Ezzeldin, and Nuria Albareda
- (i196) **ALS Phase 3 NurOwn Trial: Insight into the primary outcome through ENCALs modeled trajectories**
Namita Goyal, Jonathan Katz*, Nathan Staff, Jenny Li, Ralph Kern, Merit Cudkowicz, James Berry, Anthony Windebank, Robert Brown, Robert Miller, Matthew Burford, Bruno Boulanger, Munish Mehra, Revital Aricha, Yael Gothelf, Stacy Lindborg
- (i197) **Preliminary Biomarker Findings from the RESCUE-ALS Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS**
Steve Vucic PhD, DSc, FRACP, FAHMS, Northcott Chair of Neurology, Director Brain and Nerve Research Center; Parvathi Menon PhD, FRACP, Clinical Study Director and Clinical Senior Lecturer; William Huynh PhD, FRACP, Clinical Study Director and Neurologist; Colin Mahoney, PhD, MB, MRCPI, Clinician Scientist and Neurologist; Karen S. Ho, PhD MSc, Head, Translational Medicine, Austin Rynders, RN, Senior Director, Clinical Operations; Jacob Evan, Clinical Operations Manager; Jeremy Evan, PA-C, Clinical Operations Lead; Robert Glanzman, MD FAAN, Chief Medical Officer; Michael T. Hotchkin, Chief Development Officer; Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS, Bushel Chair of Neurology, Professor of Medicine, Central Clinical School and Co-Director, Discovery and Translation, Brain and Mind Centre

- (i198) **RESCUE-ALS Trial Results: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS**
Steve Vucic PhD, DSc, FRACP, FAHMS, Northcott Chair of Neurology, Director Brain and Nerve Research Center; Parvathi Menon PhD, FRACP, Clinical Study Director and Clinical Senior Lecturer; William Huynh PhD, FRACP, Clinical Study Director and Neurologist; Colin Mahoney, PhD, MB, MRCPI, Clinician Scientist and Neurologist; Karen S. Ho, PhD MSc, Head, Translational Medicine; Austin Rynders, RN, Senior Director, Clinical Operations; Jacob Evan, Clinical Operations Manager; Jeremy Evan, PA-C, Clinical Operations Lead; Robert Glanzman, MD FAAN, Chief Medical Officer; Michael T. Hotchkin, Chief Development Officer; Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS, Bushel Chair of Neurology, Professor of Medicine, Central Clinical School and Co-Director, Discovery and Translation, Brain and Mind Centre
- (i199) **Evidence for a Potential Survival Benefit in ALS with CNM-Au8 Treatment: Interim Results from the RESCUE-ALS Trial Long-Term Open Label Extension**
Steve Vucic PhD, DSc, FRACP, FAHMS, Parvathi Menon PhD, FRACP, William Huynh PhD, FRACP, Colin Mahoney, PhD, MB, MRCPI, Karen S. Ho, PhD MSc, Austin Rynders, RN, Jacob Evan, Jeremy Evan, PA-C, Robert Glanzman, MD FAAN, Michael T. Hotchkin, Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS
- (i200) **Interim ALS Specific Quality of Life Results from the Long-Term Open Label Extension of RESCUE-ALS, a Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS**
Steve Vucic PhD, DSc, FRACP, FAHMS, Northcott Chair of Neurology, Director Brain and Nerve Research Center; Parvathi Menon PhD, FRACP, Clinical Study Director and Clinical Senior Lecturer; William Huynh PhD, FRACP, Clinical Study Director and Neurologist; Colin Mahoney, PhD, MB, MRCPI, Clinician Scientist and Neurologist; Karen S. Ho, PhD MSc, Head, Translational Medicine; Austin Rynders, RN, Senior Director, Clinical Operations; Jacob Evan, Clinical Operations Manager; Jeremy Evan, PA-C, Clinical Operations Lead; Robert Glanzman, MD FAAN, Chief Medical Officer; Michael T. Hotchkin, Chief Development Officer; Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS, Bushel Chair of Neurology, Professor of Medicine, Central Clinical School and Co-Director, Discovery and Translation, Brain and Mind Centre
- (i201) **Adapting an adaptive randomised control trial for motor neuron disease to covid-19 pressures**
Amy Stenson, Rachel S Dakin, Judith Newton, Dawn Lyle, Christine Weaver, Jill Williamson, Suvankar Pal, Siddharthan Chandran

Cell Biology

- (j202) **Mislocalization of FUS in adult projection neurons impairs social memory and executive functions**
Raphaelle Cassel R*, Félicie Lorenc, Stéphane Dieterle, Claudia De Tapia, Salim Megat, Luc Dupuis
- (j203) **Involvement of oligodendrocytes in amyotrophic lateral sclerosis linked to Fused in Sarcoma protein**
Marguerite Jamet*, Luc Dupuis, Jose-Luis Gonzalez de Aguilar
- (j204) **An arginine mono-methylation of TDP-43 regulates its function in translational control**
Sarah Müller*, Katharina Limm, Sarah J. Brockmann, Lea-Marie Mauder, Lorena Decker, Sonja Menge, Marco Zimmel, Peter J. Oefner, Albert C. Ludolph, Jochen H. Weishaupt, Axel Freischmidt
- (j205) **Lipid defects and enhanced ER stress susceptibility in iPSCs derived oligodendrocytes with an amyotrophic lateral sclerosis causing FUS mutation**
Yingli Zhu*, Katrien Neyrinck, Arun Tharkeshwar, Jonathan De Smedt, Fatemeharefeh Nami, Wenting Guo, Melissa Nijs, Yoke Chin Chai, Rodrigo Furtado Madeiro da Costa, Ludo Van Den Bosch, Catherine Verfaillie
- (j206) **Proteomics suggest a general role of the fragile-X protein family in ALS-related protein aggregation**
Sonja Menge*, Lorena Decker, Sarah Müller, Albert C. Ludolph, Patrick Oeckl, Axel Freischmidt
- (j207) **CNM-Au8 Gold Catalytic Activity Protects Neurons Against Degeneration and Death in Multiple in vitro Models of Amyotrophic Lateral Sclerosis**
Karen S. Ho*, Jean-Philippe Richard, Arens Taga, Michael Bekier, Alexandre Henriques, Noëlle Callizot, Michael T Hotchkyn, Sami J Barmada, and Nicholas J Maragakis
- (j208) **Selective Vulnerability of Tripartite Synapses in Amyotrophic Lateral Sclerosis**
MJ Broadhead*, C Bonthron, J Waddington, WV Smith, MF Lopez, S Burley, J Valli, F Zhu, NH Komiyama, C Smith, SGN Grant, GB Miles
- (j209) **Physiological tissue-specific and age-related reduction of mouse TDP-43 levels is regulated by epigenetic modifications**
Miriam Pacetti, Laura De Conti, Luciano E Marasco, Maurizio Romano, Mohammad M Rashid, Martina Nubiè, Lubna Abou Assali, Francisco E Baralle, Marco Baralle
- (j210) **The motoneuronal receptorome in ALS reveals adrenergic entry points to modulate MN excitability and firing**
Stefano Antonucci, Guillaume Caron, Marcin Bącznyk, Daniel Zytnicki
- (j211) **Post-transcriptional regulation of the fragile-x protein family in ALS**
Lorena Decker*, Sarah Müller, Sonja Menge, Albert C. Ludolph, Axel Freischmidt
- (j212) **Mislocalization induced changes in the TDP-43 interactome**
Jerneja Nimač*, Sonja Prpar Mihevc, Julija Mazej, Helena Motaln, Eva Ogorevc, Boris Rogelj

- (j213) **Deciphering the effect of FUS mutations on motor neuron axonal pathology in ALS**
Rianne de Jongh*, Anna F. Wiersema, Svetlana Pasteuning-Vuhman, Daniëlle Vonk, Max Koppers, Ariel Ionescu, Eran Perlson, Onur Basak, R. Jeroen Pasterkamp
- (j214) **Protein Homeostasis with a Twist: Assessing the Role of Triple Helical Structures for Ubiquitin Recognition by the Ubiquitin Receptor Ubiquilin-2.**
Bethany Waddington*, Dr Drew Thomson, Dr Brian Smith, Dr Thimo Kurz
- (j215) **Positive effect of exosomes derived from permanently growing human MSC on primary murine ALS motor neurons**
Thomas Gschwendtberger*, Nadine Thau-Habermann, Juliane von der Ohe, Tianjiao Luo, Ralf Hass and Susanne Petri
- (j216) **Novel Chemical Chaperones as a Potential Therapeutic Strategy for ALS**
Leenor Alfahel#, Shirel Argueti-Ostrovsky#, Shir Barel*#, Mahmood Ali Saleh, Joy Kahn, Salome Azoulay-Ginsburg, Arie Gruzman and Adrian Israelson # Equally contributed
- (j217) **Neurochondrin, an essential neural protein, has a potential role in Spinal Muscular Atrophy pathology. Could its relevance extend to other MNDs?**
Kimberley D Morrison*, Luke W Thompson, Amy Niven, Ewout J N Groen, Thomas H Gillingwater, Judith E Sleeman
- (j218) **TDP-43 M337V mESC-derived motor neurons demonstrate impaired mitochondrial respiration and glycolysis in response to oxidative stress**
Emily Carroll*, Ana Candalija, David Gordon, Kevin Talbot
- (j219) **Localization and interactions of hnRNPH in nuclear C9ORF72 G4C2 foci and cytoplasmic stress granules**
Vera Župunski*, Sonja Prpar Mihevc, Valter Bergant,, Julija Mazej, Urša Jeršek, Alfredo Castello, Gregor Gunar and Boris Rogelj
- (j220) **C9ORF72-ALS patient-derived iPSC microglia show C9orf72 haploinsufficiency, express Poly(GA)/(GP), and have a pro-inflammatory profile**
Björn F. Vahsen*, Sumedha Nalluru, Elizabeth Gray, Jakub Scaber, Mireia Carcolé, Adrian M. Isaacs, Martin R. Turner, Sally A. Cowley, Kevin Talbot
- (j221) **Pathological aggregation and exovesicle concentration in patient derived ALS model are reduced upon treatment with TDP-43 modulators**
Carlota Tosat-Bitrián*, Carmen Pérez de la Lastra, J. Alejandro Bueso, Ana Martínez, Angeles Martín-Requero, and Valle Palomo
- (j222) **TDP-43 function is relevant in MAM-dependent phospholipid synthesis**
Anna Fernández-Bernal*, Pascual Torres, Abraham Acevedo-Arozena, Pol Andrés-Benito, Mònica Povedano, Elia Obis, Isidro Ferrer, Reinald Pamplona, Manuel Portero-Otin
- (j223) **Defining the contribution of TBK1 activity in cellular response to cytotoxic stress**
Andrew Lloyd, Leonardo Amadio,, Raja Nirujogi, Dario Alessi, Gaynor Smith, Owen Peters*
- (j224) **Restoring ER-mitochondria tethering rescues TDP-43-linked damage to Ca²⁺ signaling**
Andrea Markovinovic*, Sandra María Martín Guerrero, Gábor Mórotz and Chris Miller
- (j225) **Maintaining ER- mitochondria contacts is neuroprotective in preclinical models of ALS**
Federica Pilotto*, Alexander Joseph Schmitz, Niran Maharjan, Rim Diab, Smita Saxena

- (j226) **C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation**
Nausicaa V Licata, Riccardo Cristofani *, Sally Salomonsson, Katherine M Wilson, Liam Kempthorne, Deniz Vaizoglu, Vito G D'Agostino, Daniele Pollini, Rosa Loffredo, Michael Pancher, Valentina Adami, Paola Bellosta, Antonia Ratti, Gabriella Viero, Alessandro Quattrone, Adrian M Isaacs, Angelo Poletti, Alessandro Provenzani
- (j227) **Dynamic Expression Profiles of Stressed iPSC-MNs by Translating Ribosome Affinity Purification (TRAP) from C9orf72-ALS Patients**
Yinyan Xu*, Chaitra Sathyaprakash, Ruxandra Dafinca, Jakub Scaber, Kevin Talbot
- (j228) **Senescent astrocytes drive neurodegeneration via extracellular vesicles in ALS-FTD**
Alice Migazzi *, Alessia Soldano, Paolo Vincenzo Fioretti, Luisa Donini, Laura Pasetto, Fabio Fiordaliso, Daniele Peroni, Romina Belli, Sonja Hartwig, Stefan Lehr, Vito D'Agostino, Giulia Canarutto, Silvano Piazza, Maria Pennuto, Valentina Bonetto, Toma Tebaldi, Manuela Basso
- (j229) **AMPK regulates ER-mitochondria tethering**
Valentina Basso*, Margrete Langmyhr, Kurt De Vos
- (j230) **Chemical Tools to Investigate the Molecular Mechanisms of HDAC6 in Health and Disease**
Yvonne E. Klingl*, Adrià Sicart, Carlotta Borgarelli, Robert Prior, Philip Van Damme, Steven Verhelst, Ermal Ismalaj, Wim De Borggraeve, Matthias Schoenberger & Ludo Van Den Bosch
- (j231) **In ALS dysfunction of nucleoporin 107 impairs autophagy contributing to TDP-43 aggregation**
Omar Ramirez-Núñez, Pascual Torres, Victoria Ayala, Mónica Povedano, Isidro Ferrer, Reinald Pamplona, Manuel Portero-Otin
- (j232) **Mutations in the ALS-causative genes FUS and TDP-43 cause distinct dysregulation of somatic and axonal transcriptomes**
Jik Nijssen, Salim Benlefkci*, Christoph Schweingruber, Julio Aguila, Marc-David Ruepp and Eva Hedlund
- (j233) **Dysregulation of extracellular vesicle formation and release in astrocytes from ALS patients**
Andre Varcianna*, Sarah Granger, Katie Roome, Marco Destro, Pamela Shaw, Elizabeth Seward, Laura Ferraiuolo
- (j234) **Disruption of nucleocytoplasmic transport in SOD1 ALS**
Shirel Argueti-Ostrovsky, Su-Min Lim, Bankole Aladesuyi, Sandra Diaz Garcia, John Ravits, Clotilde Lagier-Tourenne, Adrian Israelson